Diamyd T1DM Vaccine Development Update

Diamyd Medical, the developer of the Diamyd T1DM vaccine, announced its 2019 and 2020 development and regulatory strategy. The company believes it can file for Conditional Marketing Authorization in Europe by the end of 2020 followed by the initiation of a global Ph3 study in the US and EU. Below, FENIX provides thoughts and insight into the Diamyd platform.

About The Author

Matthew Maryniak

President of Fenix Group International

Matthew has been a thought leader in the high-growth therapeutic areas of diabetes and cardiovascular medicine since 2006, making regular attendance at large and small CV/met scientific meetings and an architect of novel methods for assessing market opportunities. He has over a decade of experience in leading CV/met consulting engagements, is a published author in PM360 and Diabetes Technology & Therapeutics, and has been quoted in The Pink Sheet on anti-thrombotics.

If you receive our email blasts, you already have an account.

Purchase Blast$599.00

You can read the article’s full content online after purchase.